Selected research
Industry Research
COVID-19 Drug API Industry Research Report 2026
Market perspective
The global COVID-19 Drug API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the COVID-19 Drug API market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the COVID-19 Drug API market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the COVID-19 Drug API market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of COVID-19 Drug API include Chongqing Kangle Pharmaceutical Co., Ltd., Fuan Pharmaceutical Group, Wuhan Wuyao Pharmaceutical Co., Ltd, Cinkate, Shanghai Zhongxi Sunve Pharma Co., Ltd. and Shenhua Pharmaceutical Co., Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global COVID-19 Drug API market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to COVID-19 Drug API.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
COVID-19 Drug API Market by Company
Chongqing Kangle Pharmaceutical Co., Ltd.
Fuan Pharmaceutical Group
Wuhan Wuyao Pharmaceutical Co., Ltd
Cinkate
Shanghai Zhongxi Sunve Pharma Co., Ltd.
Shenhua Pharmaceutical Co., Ltd
COVID-19 Drug API Segment by Type
Hydroxychloroquine
Chloroquine Phosphate
Others
COVID-19 Drug API Segment by Application
Tablet
Injection
COVID-19 Drug API Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global COVID-19 Drug API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of COVID-19 Drug API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of COVID-19 Drug API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of COVID-19 Drug API companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hydroxychloroquine
- Chloroquine Phosphate
- Others
Applications
- Tablet
- Injection
Companies covered
- Chongqing Kangle Pharmaceutical Co., Ltd.
- Fuan Pharmaceutical Group
- Wuhan Wuyao Pharmaceutical Co., Ltd
- Cinkate
- Shanghai Zhongxi Sunve Pharma Co., Ltd.
- Shenhua Pharmaceutical Co., Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 COVID-19 Drug API by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Hydroxychloroquine
- 2.2.3 Chloroquine Phosphate
- 2.2.4 Others
- 2.3 COVID-19 Drug API by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tablet
- 2.3.3 Injection
- 2.4 Assumptions and Limitations
3 COVID-19 Drug API Breakdown Data by Type
- 3.1 Global COVID-19 Drug API Historic Market Size by Type (2021-2026)
- 3.2 Global COVID-19 Drug API Forecasted Market Size by Type (2027-2032)
4 COVID-19 Drug API Breakdown Data by Application
- 4.1 Global COVID-19 Drug API Historic Market Size by Application (2021-2026)
- 4.2 Global COVID-19 Drug API Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global COVID-19 Drug API Market Perspective (2021-2032)
- 5.2 Global COVID-19 Drug API Growth Trends by Region
- 5.2.1 Global COVID-19 Drug API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 COVID-19 Drug API Historic Market Size by Region (2021-2026)
- 5.2.3 COVID-19 Drug API Forecasted Market Size by Region (2027-2032)
- 5.3 COVID-19 Drug API Market Dynamics
- 5.3.1 COVID-19 Drug API Industry Trends
- 5.3.2 COVID-19 Drug API Market Drivers
- 5.3.3 COVID-19 Drug API Market Challenges
- 5.3.4 COVID-19 Drug API Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top COVID-19 Drug API Players by Revenue
- 6.1.1 Global Top COVID-19 Drug API Players by Revenue (2021-2026)
- 6.1.2 Global COVID-19 Drug API Revenue Market Share by Players (2021-2026)
- 6.2 Global COVID-19 Drug API Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of COVID-19 Drug API Head Office and Area Served
- 6.4 Global COVID-19 Drug API Players, Product Type & Application
- 6.5 Global COVID-19 Drug API Manufacturers Established Date
- 6.6 Global COVID-19 Drug API Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America COVID-19 Drug API Market Size (2021-2032)
- 7.2 North America COVID-19 Drug API Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America COVID-19 Drug API Market Size by Country (2021-2026)
- 7.4 North America COVID-19 Drug API Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe COVID-19 Drug API Market Size (2021-2032)
- 8.2 Europe COVID-19 Drug API Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe COVID-19 Drug API Market Size by Country (2021-2026)
- 8.4 Europe COVID-19 Drug API Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific COVID-19 Drug API Market Size (2021-2032)
- 9.2 Asia-Pacific COVID-19 Drug API Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific COVID-19 Drug API Market Size by Country (2021-2026)
- 9.4 Asia-Pacific COVID-19 Drug API Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America COVID-19 Drug API Market Size (2021-2032)
- 10.2 South America COVID-19 Drug API Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America COVID-19 Drug API Market Size by Country (2021-2026)
- 10.4 South America COVID-19 Drug API Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa COVID-19 Drug API Market Size (2021-2032)
- 11.2 Middle East & Africa COVID-19 Drug API Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa COVID-19 Drug API Market Size by Country (2021-2026)
- 11.4 Middle East & Africa COVID-19 Drug API Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Chongqing Kangle Pharmaceutical Co., Ltd.
- 12.1.1 Chongqing Kangle Pharmaceutical Co., Ltd. Company Information
- 12.1.2 Chongqing Kangle Pharmaceutical Co., Ltd. Business Overview
- 12.1.3 Chongqing Kangle Pharmaceutical Co., Ltd. Revenue in COVID-19 Drug API Business (2021-2026)
- 12.1.4 Chongqing Kangle Pharmaceutical Co., Ltd. COVID-19 Drug API Product Portfolio
- 12.1.5 Chongqing Kangle Pharmaceutical Co., Ltd. Recent Developments
- 12.2 Fuan Pharmaceutical Group
- 12.2.1 Fuan Pharmaceutical Group Company Information
- 12.2.2 Fuan Pharmaceutical Group Business Overview
- 12.2.3 Fuan Pharmaceutical Group Revenue in COVID-19 Drug API Business (2021-2026)
- 12.2.4 Fuan Pharmaceutical Group COVID-19 Drug API Product Portfolio
- 12.2.5 Fuan Pharmaceutical Group Recent Developments
- 12.3 Wuhan Wuyao Pharmaceutical Co., Ltd
- 12.3.1 Wuhan Wuyao Pharmaceutical Co., Ltd Company Information
- 12.3.2 Wuhan Wuyao Pharmaceutical Co., Ltd Business Overview
- 12.3.3 Wuhan Wuyao Pharmaceutical Co., Ltd Revenue in COVID-19 Drug API Business (2021-2026)
- 12.3.4 Wuhan Wuyao Pharmaceutical Co., Ltd COVID-19 Drug API Product Portfolio
- 12.3.5 Wuhan Wuyao Pharmaceutical Co., Ltd Recent Developments
- 12.4 Cinkate
- 12.4.1 Cinkate Company Information
- 12.4.2 Cinkate Business Overview
- 12.4.3 Cinkate Revenue in COVID-19 Drug API Business (2021-2026)
- 12.4.4 Cinkate COVID-19 Drug API Product Portfolio
- 12.4.5 Cinkate Recent Developments
- 12.5 Shanghai Zhongxi Sunve Pharma Co., Ltd.
- 12.5.1 Shanghai Zhongxi Sunve Pharma Co., Ltd. Company Information
- 12.5.2 Shanghai Zhongxi Sunve Pharma Co., Ltd. Business Overview
- 12.5.3 Shanghai Zhongxi Sunve Pharma Co., Ltd. Revenue in COVID-19 Drug API Business (2021-2026)
- 12.5.4 Shanghai Zhongxi Sunve Pharma Co., Ltd. COVID-19 Drug API Product Portfolio
- 12.5.5 Shanghai Zhongxi Sunve Pharma Co., Ltd. Recent Developments
- 12.6 Shenhua Pharmaceutical Co., Ltd
- 12.6.1 Shenhua Pharmaceutical Co., Ltd Company Information
- 12.6.2 Shenhua Pharmaceutical Co., Ltd Business Overview
- 12.6.3 Shenhua Pharmaceutical Co., Ltd Revenue in COVID-19 Drug API Business (2021-2026)
- 12.6.4 Shenhua Pharmaceutical Co., Ltd COVID-19 Drug API Product Portfolio
- 12.6.5 Shenhua Pharmaceutical Co., Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst